Diagnostic items for US scoring system.

<p>Diagnostic items for US scoring system.</p

US score system and probability and risk of SS in SS or non-SS patients who are compatible with AECG or ACR criteria.

<p>US score system and probability and risk of SS in SS or non-SS patients who are compatible with AECG or ACR criteria.</p

Diagnostic ability of combined classification system of 2016 ACR/EULAR and AECG criteria-based US scores for SS in 40 SS and 22 non-SS patients^a.

<p>Diagnostic ability of combined classification system of 2016 ACR/EULAR and AECG criteria-based US scores for SS in 40 SS and 22 non-SS patients<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0195113#t003fn001" target="_blank">^a</a>.</p

Representative US images/scores, ACR/EULAR scores, and integrated ACR/EULAR plus US scores vs. clinical SS diagnosis.

<p>Five patients (<b>A</b>-<b>E</b>) were clinically diagnosed as SS or non-SS by rheumatologists (clinical diagnosis). US grades were calculated as described in the text. ACR/EULAR scores were calculated based on the 5 test (serological test for anti-SS-A antibodies, labial salivary gland biopsy, ocular staining test, and salivary flow test) as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0195113#pone.0195113.ref001" target="_blank">1</a>], except for the salivary flow test, which was performed by Saxon test. Patients were diagnosed as SS or non-SS based on the ACR/EULAR criteria (threshold score ≥4) or on the integrated ACR/EULAR plus US scores (threshold score ≥5, using assigned US score of 3) as described in the text. Patients were also classified into SS or non-SS based on the AECG or ACR classification criteria as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0195113#pone.0195113.ref010" target="_blank">10</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0195113#pone.0195113.ref011" target="_blank">11</a>]. Two patients (<b>C</b> and <b>E</b>) whose results are shown in bold were those with different classification results between the ACR/EULAR criteria and the clinical diagnosis by rheumatologists, but with the same results between the integrated ACR/EULAR plus US criteria and the clinical diagnosis.</p

Diagnostic ability of combined classification system of 2016 ACR/EULAR and AECG criteria-based US scores for primary SS in 23 SS and 20 non-SS patients^a.

<p>Diagnostic ability of combined classification system of 2016 ACR/EULAR and AECG criteria-based US scores for primary SS in 23 SS and 20 non-SS patients<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0195113#t004fn001" target="_blank">^a</a>.</p

Cross-validation of single or combined criteria for SS.

<p>Cross-validation of single or combined criteria for SS.</p

Integrated score system based on the ACR/EULAR and US classifications.

<p>Integrated score system based on the ACR/EULAR and US classifications.</p

Integrated sorting, concentration and real time PCR based detection system for sensitive detection of microorganisms

<p><b>(a) Time course of the disease activity score over 24 weeks following the initiation of tofacitinib treatment with or without concomitant use of MTX.</b> Data were analyzed by the LOCF method. Points represent means. * p < 0.0001 versus baseline by the Wilcoxon signed rank test. † p < 0.05 versus baseline by the Wilcoxon signed rank test. <b>(b) The proportion of disease activity at 24 weeks after initiation of tofacitinib treatment with or without concomitant use of MTX.</b> Disease activity was categorized as follows. DAS 28-ESR <2.6(remission), 2.6-≤3.2(LDA), 3.2-≤5.1(MDA), 5.1<(HDA). <i>MTX</i> methotrexate, <i>LOCF</i> last observation carried forward, <i>ESR</i> erythrocyte sedimentation rate, <i>DAS</i> disease activity score, <i>LDA</i> low disease activity, <i>MDA</i> moderate disease activity, <i>HDA</i> high disease activity.</p